Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00012389
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : December 19, 2013
Information provided by:
National Cancer Institute (NCI)

March 3, 2001
January 27, 2003
December 19, 2013
December 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00012389 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic colorectal cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of irinotecan with or without oxaliplatin in treating patients who have metastatic colorectal cancer.


  • Compare the overall survival of patients with metastatic colorectal cancer treated with irinotecan with or without oxaliplatin.
  • Compare the response rate, time to tumor-related worsening of symptoms, time to disease progression, onset and duration of responses, and duration of disease stabilization in these patients treated with these regimens.
  • Compare the safety of these regimens in these patients.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to Karnofsky performance status (50-60% vs 70-100%), number of metastatic organs involved (1 vs 2 or more), lactic dehydrogenase (no greater than 1.5 times upper limit of normal (ULN) vs greater than 1.5 times ULN), and prior fluorouracil chemotherapy (adjuvant vs first-line treatment for metastatic disease). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive irinotecan IV over 90 minutes on day 1.
  • Arm II: Patients receive oxaliplatin IV over 120 minutes followed by irinotecan IV over 30 minutes on day 1.

Courses repeat in each arm every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.

Patients are followed at 30 days, every 4 weeks for 3 months, and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 596 patients (298 per arm) will be accrued for this study within 18 months.

Phase 3
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: irinotecan hydrochloride
  • Drug: oxaliplatin
Not Provided
Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH Jr, Bodoky G, Habboubi N, Garay C, Olivatto LO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008 Oct 1;26(28):4544-50. doi: 10.1200/JCO.2008.17.1249.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
October 2008
Not Provided


  • Histologically or cytologically confirmed adenocarcinoma of the colon or rectum
  • Metastatic or recurrent disease that is not amenable to potentially curative treatment
  • Progressive or recurrent disease during or after 1, and only 1, regimen of fluorouracil with or without leucovorin calcium or during or within 6 months after adjuvant chemotherapy with fluorouracil and leucovorin calcium



  • 18 and over

Performance status:

  • Karnofsky 50-100%

Life expectancy:

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT/SGPT no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)


  • Creatinine no greater than 1.5 times ULN


  • No unstable angina
  • No New York Heart Association class III or IV congestive heart failure
  • No serious cardiac arrhythmia
  • No history of cardiac toxicity from fluorouracil/leucovorin calcium
  • No myocardial infarction within past 6 months


  • No interstitial pneumonia or extensive and symptomatic fibrosis of the lung


  • No uncontrolled predisposing colonic or small bowel disorder
  • No prior chronic enteropathy, chronic diarrhea, or unresolved bowel obstruction/subobstruction
  • No diabetes
  • No active infection
  • No known current peripheral neuropathy
  • No concurrent active cancer except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No intolerance of appropriate antiemetics
  • No history of anaphylaxis or potential intolerance to atropine sulfate or loperamide
  • Not pregnant or nursing
  • Negative pregnancy test


Biologic therapy:

  • Not specified


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy
  • No prior irinotecan or oxaliplatin
  • No other prior chemotherapy agents except fluorouracil with or without leucovorin calcium as first-line therapy for metastatic disease or in the adjuvant setting

Endocrine therapy:

  • Not specified


  • Prior radiotherapy to non-target lesions allowed
  • No prior radiotherapy to target lesions unless disease progression is documented within the radiation port
  • At least 3 weeks since prior radiotherapy


  • At least 4 weeks since prior major surgical procedure and recovered
  • Prior surgery for primary tumor or metastasis allowed


  • At least 30 days since prior investigational drug
  • No concurrent investigational agents
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Brazil,   Canada,   Czech Republic,   Hungary,   Poland,   United Kingdom,   United States
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Chair: Daniel G. Haller, MD Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)
October 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP